VIDEO: ‘Learn from the pandemic’ for future lung cancer clinical trial enrollment
Click Here to Manage Email Alerts
Healio spoke with Upal Basu Roy, PhD, MPH, about lung cancer clinical trials and the impact the COVID-19 pandemic had on enrollment.
According to Roy, executive director of research at LUNGevity Foundation, a “particularly important” presentation from the International Association for the Study of Lung Cancer World Conference on Lung Cancer demonstrated a 43% decrease in global trial recruitment during the early stages of the pandemic.
Though this decline was “shocking,” it was not unexpected. However, investigators implemented novel strategies, such as e-consents and remote monitoring, to start trials up again during the middle of the pandemic.
“These strategies, in my opinion, are actually helpful in general because the burden of clinical trial participation is immense,” Roy said. “If we can learn from the pandemic and use some of these strategies, even beyond the pandemic I think it’s a win-win for everyone.”
Reference:
- Smeltzer M, et al. Plenary PL02.09. Presented at: International Association for the Study of Lung Cancer World Conference on Lung Cancer (virtual meeting); Sept. 8-14, 2021.
Collapse
Read more about
Click Here to Manage Email Alerts